Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2026)

Crinetics Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 14.34% year-over-year to $12.5 million in Q1 2026; TTM through Mar 2026 was $49.5 million, a 24.65% increase from a year earlier, with the FY2025 full-year figure at $51.6 million, up 26.19% from the prior year.
• Non Operating Income advanced to $12.5 million in Q1 2026 per CRNX's latest filing, from $11.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $14.6 million in Q1 2025 and bottomed at -$81000.0 in Q2 2022.
• The 5-year median for Non Operating Income is $6.8 million (2023), against an average of $6.6 million.
• Across the five-year window, Non Operating Income slumped 179.31% in 2022 and jumped 103753.85% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $92000.0 in 2022, then soared by 7250.0% to $6.8 million in 2023, then soared by 109.26% to $14.2 million in 2024, then fell by 22.04% to $11.0 million in 2025, then rose by 13.62% to $12.5 million in 2026.
• Per Business Quant, the three latest CRNX Non Operating Income figures stand at $12.5 million (Q1 2026), $11.0 million (Q4 2025), and $12.5 million (Q3 2025).